A practical reference on clinical evidence: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2025-09-18. Anything still debated is marked as such rather than presented as settled.
Within the research literature, the peptide is discussed through several provisional mechanisms, including cytoprotection, modulation of growth factor signaling, and interaction with the nitric oxide system. None of these mechanisms is fully characterized, and no single pathway is universally accepted. Review articles typically note the gap between consistent animal findings and sparse human evidence. The compound is classified as a research chemical rather than an approved pharmaceutical, which shapes how studies are designed, funded, and reported.
BPC-157 is a synthetic pentadecapeptide with the sequence GEPPPGKPADDAGLV, corresponding to a partial fragment of a larger protein detected in human gastric juice. The name derives from the parent protein designation BPC, an abbreviation of body protection compound, with 157 acting as a fraction or batch identifier used by the original investigators. Its molecular weight is approximately 1419 daltons, and the chain contains no unusual residues or disulfide bridges. In the literature it is described as a short, water-soluble fragment rather than a complete natural protein.
Most early work on this peptide originated in the 1990s from a research group in Zagreb, Croatia, relying on animal models and cell cultures. Reported observations included effects on gastrointestinal lesion healing, tendon fibroblast migration, and blood vessel formation under controlled laboratory conditions. These findings come predominantly from rodent studies and in vitro assays rather than from human trials. Controlled human data remain limited, and the degree to which animal results translate to human physiology is an open question rather than a settled fact.
Most published work on BPC-157 comes from animal experiments rather than controlled human trials. Rodent models have examined its effects on gastrointestinal lesions, tendon and ligament injury, and blood vessel formation. These studies are often small and originate from a limited number of research groups, which affects how broadly the findings can be generalized. No large randomized human trial has been reported in the peer-reviewed literature. Discussion of the compound therefore rests largely on preclinical data, and questions about its effects in people remain open rather than settled.
Several mechanisms have been proposed to explain the activity observed in animal models. The most frequently cited involve signaling through vascular endothelial growth factor receptor 2 and modulation of the nitric oxide system. Researchers have also described interactions with protective pathways in the gut lining. These proposed mechanisms appear in the literature as hypotheses supported by preclinical observations, not as confirmed pathways in humans. The precise way the peptide produces its reported effects, and whether those effects carry across species, remain areas of active and unresolved investigation.
BPC-157 is a synthetic pentadecapeptide, meaning it consists of fifteen amino acids joined in a single chain. Its sequence is Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val, a fragment corresponding to part of a larger protein found in human gastric juice. The peptide was first described in the 1990s by researchers in Zagreb who were studying gastric protective factors. It is not a naturally circulating hormone; it is a laboratory-made fragment derived from a stomach protein. The name is an abbreviation of body protection compound, with the number referring to the fragment's position in the source protein.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C62H98N16O22 | computed for the free peptide |
| Molecular weight | about 1419 Da | monoisotopic mass near 1418.7 |
| Amino acid count | 15 | single chain, no disulfide bonds |
| Solubility | freely soluble in water | also dissolves in saline and phosphate buffer |
| Common synonyms | pentadecapeptide BPC, BPC 157 | fragment notation varies by source |
Most published findings come from rodent experiments using induced injury or surgical models. Human reports remain scarce and are largely observational, which limits how much can be stated with confidence. Questions about absorption, distribution, metabolism, and clearance in people are still open. Dose translation between species is likewise unresolved. Researchers tend to read the animal literature as a starting point rather than a settled account.
BPC-157 is a synthetic peptide composed of fifteen amino acids. Its sequence corresponds to part of a protein found in human gastric juice, which is the origin of the "body protection compound" label. In laboratory work the material is treated as a defined research chemical rather than a finished product. Published research has centered on animal models, and the peptide is not an approved medicine in most countries.
Some properties, such as the peptide's sequence and molecular mass, are firmly established. Other claims, particularly about mechanism and clinical benefit, remain open questions. Proposed mechanisms include effects on nitric oxide signaling and on cell migration, but these are hypotheses supported by limited evidence. Reviewers often note that the field lacks large controlled human trials. Positive animal findings are best treated as signals for further study rather than as settled conclusions.
Most published studies examine BPC-157 in animal models rather than in humans. Common subjects include rats and mice, and researchers often use models of tissue injury, surgery, or induced inflammation. Reported endpoints include healing rates, blood vessel formation, and markers of tissue repair. These designs provide controlled comparisons, but findings in animals do not automatically transfer to people. Human clinical data remain limited and are frequently described as preliminary.
Purity is ordinarily reported as a percentage from reverse-phase high-performance liquid chromatography, where the area of the main peak is compared with the total peak area. Identity is confirmed by mass spectrometry, since the measured mass can be checked against the value calculated from the sequence. Some certificates also include amino acid analysis or sequence confirmation by tandem mass spectrometry. A single purity number does not describe the profile of related impurities, so the underlying chromatogram and spectrum usually carry more information than the headline figure.
Material of this kind is sold for laboratory research, and labels typically state that it is not intended for human or veterinary use. In many countries it is not an approved medicine, and sports antidoping rules place it among prohibited non-approved substances. Buyers commonly review a certificate of analysis, an independent test report, and the declared storage conditions. Batch-to-batch variation in purity and in counterion content is possible, and how much that variation affects experimental outcomes remains an open question.
Lyophilized peptide is normally kept at minus twenty degrees Celsius or colder, away from light and moisture. Powder held under those conditions is widely treated as stable for long periods, although published stability studies for this exact sequence are sparse and often come from suppliers rather than independent laboratories. Once dissolved, solutions are generally handled cold and used within a short window, because peptide bonds can hydrolyze over time. Repeated freeze-thaw cycles are usually avoided to limit losses, and exact shelf-life figures depend on the buffer and the concentration involved.
BPC-157 is a synthetic peptide built from fifteen amino acid residues. Its sequence comes from a larger protein fragment that researchers isolated from human gastric juice and described as a body protection compound. The fragment contains glycine, glutamic acid, five prolines, lysine, alanine, two aspartic acids, leucine, and valine. The number 157 in the name refers to the position of the stretch within the parent protein. Material used in laboratories is manufactured rather than extracted from stomach fluid.
The molecule carries 15 residues, a molar mass near 1419.5 g/mol, and the formula C62H98N16O22. Its structure features a proline-rich central region, a pair of adjacent aspartic acid residues, and no cysteine. The absence of cysteine means no disulfide bonds can form, which simplifies refolding and reconstitution. Suppliers usually ship the material as a freeze-dried powder that appears white to off-white. It dissolves readily in water and in saline solutions.
=== Mechanism of action === Patiromer works by binding free potassium ions in the gastrointestinal tract and releasing calcium ions for exchange, thus lowering the amount of potassium available for absorption into the bloodstream and increasing the amount that is excreted via the feces. The net effect is a reduction of potassium levels in the blood serum. Lowering of potassium levels is detectable seven hours after administration. Levels continue to decrease for at least 48 hours if treatment is continued, and remain stable for 24 hours after administration of the last dose. After this, potassium levels start to rise again over a period of at least four days.
== Interactions == The hypotensive effects of butizide can be increased by antihypertensive drugs (especially ACE inhibitors), barbiturates, tricyclic antidepressants, and ethanol. Combination with beta blockers can increase blood glucose levels; and conversely, butizide can decrease the effects of antidiabetic drugs. As butizide lowers blood potassium and magnesium levels, it can increase the effects of cardiac glycosides. It can also increase lithium toxicity. Nonsteroidal anti-inflammatory drugs can decrease the diuretic effect of butizide.
After labeling of the surface with the selected F bioactives, the constructs will be present and oriented at the membrane surface. It is expected that the FSL will be highly mobile within the membrane and the choice of lipid tail will effect is relative partitioning within the membrane. The construct unless it has flip-flop behavior is expected to remain surface presented. However, the modification is not permanent in living cells and constructs will be lost (consumed) at a rate proportional to the activity at the membrane and division rate of the cell (with dead cells remaining highly labeled). Additionally, when present in vivo with serum lipids FSLs will elute from the membrane into the plasma at a rate of about 1% per hour. In fixed cells or inactive cells (e.g. red cells) stored in serum free media the constructs are retained normally. Liposomes are easy koded by simply adding FSL Kode constructs into the preparation. Contacting koded liposomes with microplates or other surfaces can cause the labeling of the microplate surface.
Zalsupindole, also known by its code names DLX-001 and AAZ-A-154 and as (R)-5-methoxy-N,N-dimethyl-α-methylisotryptamine ((R)-5-MeO-α-Me-isoDMT), is non-hallucinogenic serotonin receptor agonist and psychoplastogen of the isotryptamine family related to psychedelic tryptamines such as dimethyltryptamine (DMT). It is under development for the treatment of major depressive disorder and other central nervous system disorders. The drug is taken orally. It acts as a partial agonist of the serotonin 5-HT2A receptor and also interacts with other serotonin receptors. The drug activates the serotonin 5-HT2A receptor with sufficiently high efficacy to promote neuroplasticity but not with adequate efficacy to cause psychedelic effects. It does not produce psychedelic-like effects in animals or humans but does produce antidepressant-like effects in animals. Zalsupindole was first described in the scientific literature by 2021. It was developed by David E. Olson and colleagues at the University of California, Davis and Delix Therapeutics. As of April 2026, it has successfully completed Phase 1 clinical trials, demonstrating positive safety and biomarker data. The FDA has cleared the Investigational New Drug (IND) application for a Phase 2 trial, which includes a study design for at-home administration.
Sources: en.wikipedia.org
== Function == Corin converts the atrial natriuretic peptide (ANP) precursor, pro-ANP, to mature ANP, a cardiac hormone that regulates salt-water balance and blood pressure. In mice, corin deficiency prevents pro-ANP processing and causes salt-sensitive hypertension. Corin may also function as a pro-brain-type natriuretic peptide convertase. Corin-mediated ANP production in the pregnant uterus promotes spiral artery remodeling and trophoblast invasion. CORIN mutations have been reported in patients with preeclampsia. In mice, corin functions in the dermal papilla to regulate coat color in an Agouti-dependent pathway.
=== Mary Conner === Mary Conner is played by Jayden Rey. Mary is D.J. and Geena's daughter. Mary is named after her deceased great-great-grandmother, Nana Mary. In Season 3, D.J. begins a new job requiring him to work long hours and often in neighboring towns. Although Geena and D.J.'s friends are checking on her throughout the day, Mary tells Darlene she is lonely. Darlene and Becky decide to have her live at the Conner house during the week without first asking D.J. He is initially angry, but relents when Mary says she wants to stay.
== Research == Biggar's research includes many different areas from different fields within molecular biology, biochemistry, and physical biochemistry. His main areas of research interest are Oxidative Cell Stress, Functional Proteomics, Bioinformatics, and Molecular Pharmacology. He is particularly known for his research in the new field of Non-histone Lysine Methylation and its relation to both functional proteomics and cell stress.
== Culture == Most of the district's news media has been either weekly or monthly publications. The earliest newspaper was the Scarborough News and Advertiser which was published weekly starting in September 1921, which lasted until the 1930s. Other short-lived papers and magazines included The Enterprise (1945–1966), Scarborough Mail (1946–1955) and The News (1952–1996) and 54east magazine (2005–2009). The last remaining English-language local newspaper was the Scarborough Mirror, which started publication in 1962 and was later acquired by the Toronto Star's community news division, Metroland. In 2023, it became an online-only publication as part of Toronto.com. A Scarborough edition of the Toronto-wide photography publication SNAP Scarborough was launched in 2009. Ming Pao Daily News is a Chinese-language newspaper whose headquarters is in the district. They started publication in 1993. In 1961, the CTV Toronto (CFTO) television channel began operating from the 9 Channel Nine Court studios at the intersection of McCowan Road and Highway 401. Today, the studio also is the headquarters of The Sports Network (TSN). Both companies produce programming at the studio. In 1970, Trillium Cable started to provide cable TV service to Scarborough. It was purchased by Shaw Cable in 1995; but later swapped with Rogers Cable in 2001. During the early days of the company, they produced several local shows for their own cable channel. These shows were produced by volunteers and showed a wide variation in quality. These shows were satirized by Mike Myers in his comedy film Wayne's World.
The majority of the population of Jammu and Kashmir is Muslim and a large minority is Hindu. Most Muslims in Jammu and Kashmir belong to the Sunni sect of Islam, especially the Gurjars, Bakarwals, Sayids, Pathans, Sheikhs, Mughals, Paharis, and Doms. As per the 2011 census of India, about 68.3% of people in Jammu and Kashmir were Muslims. Hindu made up around 28.4% of the population. Other small religious groups included Sikhs at 1.9%, Buddhists at 0.9%, and Christians at 0.3%. The population of the Kashmir Division is predominantly Muslim (96.41%) with small Hindu (2.45%) and Sikh (0.81%) communities. Shias are mostly concentrated in the Budgam district, where they form about 30–40% of the population. Among the Kashmiri Hindus, the Pandits are a significant group. The Jammu Division is predominantly Hindu (67.5%) with a significant Muslim population (30%). The Muslims form a majority in the Rajouri (63%), Poonch (90%), Doda (54%), Kishtwar (58%) and Ramban (71%) districts of Jammu, while the Hindus form a majority in Kathua (88%), Samba (86%), Jammu (84%) and Udhampur (88%) districts. Reasi district has an almost equal number of Hindus and Muslims. Most Dogras in the region are Hindus and belong to various Hindu castes. Paharis include both Hindu and Muslims. The Gurjars and Bakarwals are predominantly Sunni Muslims.
Sources: en.wikipedia.org
=== With nitrogen species === With primary amines, thionyl chloride gives sulfinylamine derivatives (RNSO), one example being N-sulfinylaniline. Thionyl chloride reacts with primary formamides to form isocyanides and with secondary formamides to give chloroiminium ions; as such a reaction with dimethylformamide will form the Vilsmeier reagent. By an analogous process, secondary amides will react with thionyl chloride to form imidoyl chlorides, with tertiary amides giving chloroiminium ions. These species are highly reactive and can be used to catalyse the conversion of carboxylic acids to acyl chlorides; they are also exploited in the Bischler–Napieralski reaction as a means of forming isoquinolines.
An overabundance of 5-HT3 receptors is reported in cocaine-conditioned rats, though 5-HT3's role is unclear. The 5-HT2 receptor (particularly the subtypes 5-HT2A, 5-HT2B and 5-HT2C) are involved in the locomotor-activating effects of cocaine. Cocaine has been demonstrated to bind as to directly stabilize the DAT transporter on the open outward-facing conformation. Further, cocaine binds in such a way as to inhibit a hydrogen bond innate to DAT. Cocaine's binding properties are such that it attaches so this hydrogen bond will not form and is blocked from formation due to the tightly locked orientation of the cocaine molecule. Research studies have suggested that the affinity for the transporter is not what is involved in the habituation of the substance so much as the conformation and binding properties to where and how on the transporter the molecule binds. Conflicting findings have challenged the widely accepted view that cocaine functions solely as a reuptake inhibitor. To induce euphoria an intravenous dose of 0.3-0.6 mg/kg of cocaine is required, which blocks 66-70% of DAT in the brain. Re-administering cocaine beyond this threshold does not significantly increase DAT occupancy but still results in an increase of euphoria which cannot be explained by reuptake inhibition alone. This discrepancy is not shared with other dopamine reuptake inhibitors like bupropion, sibutramine, mazindol or tesofensine, which have similar or higher potencies than cocaine as dopamine reuptake inhibitors.
Nucleic acid templated chemistry (NATC), or DNA-templated chemistry, is a tool used in the controlled synthesis of chemical compounds. The main advantage of NAT-chemistry (NATC) is that it allows the user to perform the chemical reaction as an intramolecular reaction. Two oligonucleotides, or their analogues, are linked via chemical groups to precursors of chemical compounds. The oligonucleotides recognize specific nucleic acids and are hybridized sterically close to each other. Afterwards, the chemical active groups interact with each other to combine the precursors into a completely new chemical compound. NATC is usually used to perform synthesis of complex compounds without the need to protect chemically active groups during the synthesis. In 1999 Pavel Sergeev suggested the use of NATC to synthesize biologically active compounds within living organisms., including use within human cells. In this application, the precursors are distributed in the whole human body and the chemical reactions are performed only within cells having specific RNA molecules. This approach allows very specific synthesis within particular tissues or within specific cells of the tissue. It is especially a new tool to deliver medications to cancer cells. Additionally biologically active compounds could be delivered to specific cells within humans to promote the targeted cells to divisions. NATC also opens the possibility to treat bacterial diseases. Many scientific groups have performed NATC in vivo to visualize eukaryotic as well as bacterial cells.
== History == In traditional oil painting as practiced by the Renaissance painter, skin glue was used to seal the canvas. This is necessary because the linseed oil that forms the base of most oil paint contains linolenic acid that will destroy the canvas fibers over time. Renaissance artists also knew that pure size (hide glue) became brittle once dry, and would mix it with oil and chalk to make a "half-ground" for canvases. Pure hide glue was usually applied only to rigid supports like panels. Though this does help to seal the canvas or panel, artists still applied a layer of "oil ground", which was often lead-based paint, in order to provide a binding layer for the final oil paint to adhere to.
==== Visible from the front or above ==== Frontal suture / Metopic suture – between the two frontal bones, prior to the fusion of the two into a single bone Sagittal suture – along the midline, between parietal bones
Sources: en.wikipedia.org
The sequence corresponds to a fragment of a protein found in human gastric juice, so related sequences are natural. The isolated fifteen-amino-acid peptide supplied for research is produced synthetically. Whether the free fragment circulates naturally in humans has not been settled.
In most jurisdictions it is not an approved medicine and is handled as a research material. Import and sale rules differ by country, and some regulators have placed it in categories that restrict human use. Status can change, so current local rules apply.
Rodent models dominate, particularly rats with induced gastric lesions, tendon injury, or vascular disruption. These designs allow controlled comparison but differ anatomically and metabolically from humans. Results from such models are commonly cited as preliminary.
It is a chain of fifteen amino acids, referred to as a pentadecapeptide. The sequence is Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. It corresponds to a fragment of a protein found in human gastric juice.